Ceftizoxime

Ceftizoxime

Ceftizoxime

Chemical compound

Ceftizoxime is a third-generation cephalosporin available for parenteral administration.[1] Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.

Quick Facts Clinical data, Trade names ...

Synthesis

Injectable third generation cephalosporin antibiotic related to cefotaxime, q.v. Exhibits broad spectrum activity and resistance to β-lactamase hydrolysis.

Ceftizoxime synthesis:[2][3]

References

  1. [1]
    Aldridge KE (1990). "An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria". Clinical Therapeutics. 12 Suppl C: 3–12. PMID 2202509.
  2. [2]
    DE 2810922, Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "New cepham compounds and processes for the production thereof", issued 29 August 1985, assigned to Fujisawa
  3. [3]
    US 4427674, Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "Cephem compounds", issued 24 January 1984, assigned to Fujisawa


Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Ceftizoxime, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.